Divergent α-synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson's disease brains with Lewy Body pathology compared to idiopathic cases

[1]  G. Halliday,et al.  LRRK2 interactions with α-synuclein in Parkinson’s disease brains and in cell models , 2012, Journal of Molecular Medicine.

[2]  A. Mamais,et al.  Phosphorylation of 4E-BP1 in the Mammalian Brain Is Not Altered by LRRK2 Expression or Pathogenic Mutations , 2012, PloS one.

[3]  D. Berwick,et al.  LRRK2 functions as a Wnt signaling scaffold, bridging cytosolic proteins and membrane-localized LRP6 , 2012, Human molecular genetics.

[4]  E. Tolosa,et al.  Age at Onset in LRRK2-Associated PD is Modified by SNCA Variants , 2012, Journal of Molecular Neuroscience.

[5]  J. Troncoso,et al.  Neurodegenerative phenotypes in an A53T α-synuclein transgenic mouse model are independent of LRRK2. , 2012, Human molecular genetics.

[6]  Christopher M. Dobson,et al.  Direct Observation of the Interconversion of Normal and Toxic Forms of α-Synuclein , 2012, Cell.

[7]  D. Shimshek,et al.  High LRRK2 Levels Fail to Induce or Exacerbate Neuronal Alpha-Synucleinopathy in Mouse Brain , 2012, PloS one.

[8]  A. West,et al.  GTPase Activity and Neuronal Toxicity of Parkinson's Disease–Associated LRRK2 Is Regulated by ArfGAP1 , 2012, PLoS genetics.

[9]  Clinical and Pathological Characteristics of LRRK2 G2019S Patients with PD , 2012, Journal of Molecular Neuroscience.

[10]  J. Holton,et al.  LRRK2 expression in idiopathic and G2019S positive Parkinson's disease subjects: a morphological and quantitative study , 2011, Neuropathology and applied neurobiology.

[11]  Kostas Vekrellis,et al.  Pathological roles of α-synuclein in neurological disorders , 2011, The Lancet Neurology.

[12]  J. Ioannidis,et al.  Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case–control study , 2011, The Lancet Neurology.

[13]  L. White,et al.  Subclinical signs in LRRK2 mutation carriers. , 2011, Parkinsonism & related disorders.

[14]  Michael J. Devine,et al.  Pathogenic LRRK2 Mutations Do Not Alter Gene Expression in Cell Model Systems or Human Brain Tissue , 2011, PloS one.

[15]  R. Teshima,et al.  α-Synuclein aggregation and transmission are enhanced by leucine-rich repeat kinase 2 in human neuroblastoma SH-SY5Y cells. , 2011, Biological & pharmaceutical bulletin.

[16]  D. Miller,et al.  Reduced Content of α-Synuclein in Peripheral Blood Leukocytes of Patients with LRRK2-Associated Parkinson’s Disease , 2011, Bulletin of Experimental Biology and Medicine.

[17]  D. Howells,et al.  Changes in the solubility and phosphorylation of α-synuclein over the course of Parkinson’s disease , 2011, Acta Neuropathologica.

[18]  Mohamad Saad,et al.  Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies , 2011, The Lancet.

[19]  W. Poewe,et al.  Brain stem pathology in Parkinson's disease: An evaluation of the Braak staging model , 2010, Movement disorders : official journal of the Movement Disorder Society.

[20]  W. Schulz-Schaeffer.  The synaptic pathology of α-synuclein aggregation in dementia with Lewy bodies, Parkinson’s disease and Parkinson’s disease dementia , 2010, Acta Neuropathologica.

[21]  I. Ferrer,et al.  Involvement of the cerebral cortex in Parkinson disease linked with G2019S LRRK2 mutation without cognitive impairment , 2010, Acta Neuropathologica.

[22]  D. Dickson,et al.  Leucine-Rich Repeat Kinase 2 Gene-Associated Disease: Redefining Genotype-Phenotype Correlation , 2010, Neurodegenerative Diseases.

[23]  I. Martin,et al.  The impact of genetic research on our understanding of Parkinson's disease. , 2010, Progress in brain research.

[24]  H. Cai,et al.  Leucine-Rich Repeat Kinase 2 Regulates the Progression of Neuropathology Induced by Parkinson's-Disease-Related Mutant α-synuclein , 2009, Neuron.

[25]  M. Beal,et al.  Metabolomic Profiling in LRRK2-Related Parkinson's Disease , 2009, PloS one.

[26]  H. Qing,et al.  Lrrk2 phosphorylates alpha synuclein at serine 129: Parkinson disease implications. , 2009, Biochemical and biophysical research communications.

[27]  A. Pisani,et al.  R1441C mutation in LRRK2 impairs dopaminergic neurotransmission in mice , 2009, Proceedings of the National Academy of Sciences.

[28]  Rosa M. Sancho,et al.  Mutations in the LRRK2 Roc-COR tandem domain link Parkinson's disease to Wnt signalling pathways , 2009, Human molecular genetics.

[29]  M. Cookson,et al.  Leucine-rich repeat kinase 2 mutations and Parkinson’s disease: three questions , 2009, ASN neuro.

[30]  J. Tepper,et al.  Basal ganglia control of substantia nigra dopaminergic neurons. , 2009, Journal of neural transmission. Supplementum.

[31]  M. Cookson.  α-Synuclein and neuronal cell death , 2009, Molecular Neurodegeneration.

[32]  G. Fisone,et al.  Lrrk2 and α-synuclein are co-regulated in rodent striatum , 2008, Molecular and Cellular Neuroscience.

[33]  R. Takahashi,et al.  Phosphorylation of 4E‐BP by LRRK2 affects the maintenance of dopaminergic neurons in Drosophila , 2008, The EMBO journal.

[34]  E. Tolosa,et al.  Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study , 2008, The Lancet Neurology.

[35]  Xinglong Wang,et al.  The Roc domain of leucine‐rich repeat kinase 2 is sufficient for interaction with microtubules , 2008, Journal of neuroscience research.

[36]  G. Muntané,et al.  Phosphorylation of tau and α-synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer’s disease, and in Parkinson’s disease and related α-synucleinopathies , 2008, Neuroscience.

[37]  Elisabet Englund,et al.  Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation , 2008, Nature Medicine.

[38]  M. Cookson,et al.  Genetic neuropathology of Parkinson's disease. , 2008, International journal of clinical and experimental pathology.

[39]  R. Nichols,et al.  LRRK2 phosphorylates moesin at threonine-558: characterization of how Parkinson's disease mutants affect kinase activity. , 2007, The Biochemical journal.

[40]  L. Skipper,et al.  Pathogenic mutations in Parkinson disease , 2007, Human mutation.

[41]  T. Iwatsubo,et al.  Accumulation of phosphorylated α‐synuclein in dopaminergic neurons of transgenic mice that express human α‐synuclein , 2007 .

[42]  G. Muntané,et al.  2.319 Phosphorylation of tau and alpha-synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer's Disease, and in Parkinson's disease and related alpha-synucleinopathies , 2007 .

[43]  Jan Booij,et al.  SPECT imaging of the dopaminergic system in (premotor) Parkinson's disease. , 2007, Parkinsonism & related disorders.

[44]  T. Iwatsubo,et al.  Accumulation of phosphorylated alpha-synuclein in dopaminergic neurons of transgenic mice that express human alpha-synuclein. , 2007, Journal of neuroscience research.

[45]  R. Barbour,et al.  Phosphorylation of Ser-129 Is the Dominant Pathological Modification of α-Synuclein in Familial and Sporadic Lewy Body Disease* , 2006, Journal of Biological Chemistry.

[46]  C. Ross,et al.  Kinase activity of mutant LRRK2 mediates neuronal toxicity , 2006, Nature Neuroscience.

[47]  David W. Miller,et al.  Kinase activity is required for the toxic effects of mutant LRRK2/dardarin , 2006, Neurobiology of Disease.

[48]  M. Onofrj,et al.  Diagnosis and management of dementia with Lewy bodies: Third report of the DLB Consortium , 2006, Neurology.

[49]  Matthew J. Farrer,et al.  LRRK2 in Parkinson's disease: protein domains and functional insights , 2006, Trends in Neurosciences.

[50]  S Minoshima,et al.  Diagnosis and management of dementia with Lewy bodies , 2005, Neurology.

[51]  Andrew B West,et al.  Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[52]  C. Ross,et al.  Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[53]  Nicholas W Wood,et al.  A common LRRK2 mutation in idiopathic Parkinson's disease , 2005, The Lancet.

[54]  Thomas Meitinger,et al.  Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology , 2004, Neuron.

[55]  Andrew Lees,et al.  Cloning of the Gene Containing Mutations that Cause PARK8-Linked Parkinson's Disease , 2004, Neuron.

[56]  Mark R. Segal,et al.  Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death , 2004, Nature.

[57]  David W. Miller,et al.  α-Synuclein in blood and brain from familial Parkinson disease with SNCA locus triplication , 2004, Neurology.

[58]  H. Braak,et al.  Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.

[59]  Hideo Fujiwara,et al.  Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. , 2002, The Journal of clinical investigation.

[60]  E. Masliah,et al.  α-Synuclein is phosphorylated in synucleinopathy lesions , 2002, Nature Cell Biology.

[61]  E. Masliah,et al.  alpha-Synuclein is phosphorylated in synucleinopathy lesions. , 2002, Nature cell biology.

[62]  J. Trojanowski,et al.  Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. , 2002, The Journal of clinical investigation.

[63]  C. Masters,et al.  The solubility of α‐synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson's disease , 2001 .

[64]  C. Masters,et al.  The solubility of alpha-synuclein in multiple system atrophy differs from that of dementia with Lewy bodies and Parkinson's disease. , 2001, Journal of neurochemistry.

[65]  H. Zoghbi,et al.  Neurobiology of disease , 2000, Current Opinion in Neurobiology.

[66]  J. Trojanowski,et al.  Neurodegeneration with Brain Iron Accumulation, Type 1 Is Characterized by α-, β-, and γ-Synuclein Neuropathology , 2000 .

[67]  C. Masters,et al.  Accumulation of Insoluble α-Synuclein in Dementia with Lewy Bodies , 2000, Neurobiology of Disease.

[68]  C. Masters,et al.  Accumulation of insoluble alpha-synuclein in dementia with Lewy bodies. , 2000, Neurobiology of disease.

[69]  M G Spillantini,et al.  Alpha-synuclein in Lewy bodies. , 1997, Nature.